Literature DB >> 27235610

Update in Hypertension Therapy.

Leonard A Mankin1.   

Abstract

Hypertension is the leading cause of early mortality in the world, and reduction of blood pressure can help to reduce that burden. There is an enormous and ever-expanding body of literature on hypertension, with a 2016 Medline search for hypertension retrieving more than 113,000 publications. Recent guidelines from major societies have been published, and often present conflicting recommendations based on the same data. Using a question-and-answer format, this article reviews some of the recent developments and opinions on management of blood pressure and provides practical suggestions for management in the clinical arena.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antihypertensives; Blood pressure; Blood pressure goals; Hypertension; SGLT-2 inhibitors; Spironolactone; Therapy

Mesh:

Substances:

Year:  2016        PMID: 27235610     DOI: 10.1016/j.mcna.2016.03.005

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  3 in total

1.  Contribution of Baroreflex Afferent Pathway to NPY-Mediated Regulation of Blood Pressure in Rats.

Authors:  Yang Liu; Shu-Yang Zhao; Yan Feng; Jie Sun; Xiao-Long Lu; Qiu-Xin Yan; Ying Li; Zhuo Liu; Lu-Qi Wang; Xun Sun; Shijun Li; Guo-Fen Qiao; Bai-Yan Li
Journal:  Neurosci Bull       Date:  2019-10-29       Impact factor: 5.203

2.  Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain-Its Possible Clinical Applications.

Authors:  Izabela Zakrocka; Katarzyna M Targowska-Duda; Artur Wnorowski; Tomasz Kocki; Krzysztof Jóźwiak; Waldemar A Turski
Journal:  Neurotox Res       Date:  2017-07-21       Impact factor: 3.911

3.  Angiotensin-Converting Enzyme 2 in the Rostral Ventrolateral Medulla Regulates Cholinergic Signaling and Cardiovascular and Sympathetic Responses in Hypertensive Rats.

Authors:  Yu Deng; Xing Tan; Miao-Ling Li; Wei-Zhong Wang; Yang-Kai Wang
Journal:  Neurosci Bull       Date:  2018-10-15       Impact factor: 5.203

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.